Racemethorphan

Racemethorphan

SCHEMBL4894005

Br.COc1ccc2c(c1)[C@@]13CCCC[C@@H]1[C@@H](C2)N(C)CC3.O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GRIN2ASIGMAR1

The experimentally established mechanism targets of Racemethorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2A known ✓ Q12879 7/20 0.95
SIGMAR1 known ✓ Q99720 6/20 0.95
CYP2D6 P10635 2/20 1.00
LMNA P02545 1/20 1.00
PMP22 Q01453 1/20 1.00
CYP3A4 P08684 1/20 0.98
GRIN1 Q05586 7/20 0.95
GRIN2D O15399 6/20 0.95
GRIN3B O60391 6/20 0.95
GRIN2B Q13224 6/20 0.95
GRIN2C Q14957 6/20 0.95
GRIN3A Q8TCU5 6/20 0.95
OPRM1 P35372 5/20 0.95
SLC6A4 P31645 4/20 0.95
TMEM97 Q5BJF2 3/20 0.95
SLC6A2 P23975 2/20 0.95
OPRK1 P41145 2/20 0.95
SLC22A1 O15245 1/20 0.95
ADRA2A P08913 1/20 0.95
TSHR P16473 1/20 0.95

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Levomethorphan SCHEMBL4910539 1.00 CYP2D6 (1.00) CYP2D6LMNAPMP22CYP3A4GRIN1
Dextromethorphan SCHEMBL29359586 1.00 CYP2D6 (1.00) CYP2D6LMNAPMP22CYP3A4GRIN1
Dextromethorphan SCHEMBL121923 1.00 CYP2D6 (1.00) CYP2D6LMNAPMP22CYP3A4GRIN1
Dextromethorphan SCHEMBL1321395 1.00 CYP2D6 (1.00) CYP2D6LMNAPMP22CYP3A4GRIN1
Dextromethorphan SCHEMBL4532860 1.00 CYP2D6 (1.00) CYP2D6LMNAPMP22CYP3A4GRIN1
Racemethorphan SCHEMBL30052214 1.00 CYP2D6 (1.00) CYP2D6LMNAPMP22CYP3A4GRIN1
Dextromethorphan SCHEMBL4882307 0.99 CYP2D6 (0.98) CYP2D6LMNAPMP22CYP3A4GRIN1
Dextromethorphan SCHEMBL121924 0.99 CYP3A4 (1.00) CYP2D6LMNAPMP22CYP3A4GRIN1
Dextromethorphan SCHEMBL3325972 0.99 GRIN1 (0.98) CYP2D6LMNAPMP22CYP3A4GRIN1
Racemethorphan SCHEMBL6855351 0.99 CYP3A4 (1.00) CYP2D6LMNAPMP22CYP3A4GRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150056288-A1 MODIFIED RELEASE LIQUID PHARMACEUTICAL COMPOSITION COMPRISING BROMOPHENIRAMINE, PSEUDOEPHEDRINE AND DEXTROMETHORPHAN WOCKHARDT LIMITED (IN) 2015-02-26 US disclosed
US-20080176955-A1 COMBINED ADMINISTRATION OF BENZONATATE AND GUAIFENESIN VICTORY PHARMA, INC. (US) 2008-07-24 US disclosed
US-20080090878-A1 Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders BILLSTEIN STEPHAN A 2008-04-17 US disclosed
US-20070231268-A1 Methods and compositions for deterring abuse of orally administered pharmaceutical products ACURA PHARMACEUTICALS, INC. 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150056288-A1 MODIFIED RELEASE LIQUID PHARMACEUTICAL COMPOSITION COMPRISING BROMOPHENIRAMINE, PSEUDOEPHEDRINE AND DEXTROMETHORPHAN QDPR, CYP3A43, CYP2D6 GRIN2A 915/4885SIGMAR1 12/4885CYP2D6 3/4885
US-20080176955-A1 COMBINED ADMINISTRATION OF BENZONATATE AND GUAIFENESIN OPRL1, OPRM1, GNAI3 GRIN2A 1355/4885SIGMAR1 550/4885CYP2D6 267/4885
US-20080090878-A1 Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders MLNR, HTR4, HTR3D GRIN2A 2226/4885SIGMAR1 289/4885CYP2D6 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.